<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04876027</url>
  </required_header>
  <id_info>
    <org_study_id>GLP-1RAs PCOS</org_study_id>
    <nct_id>NCT04876027</nct_id>
  </id_info>
  <brief_title>GLP-1 RAs in Patients With Polycystic Ovarian Syndrome (PCOS)</brief_title>
  <official_title>GLP-1 RAs and Calorie Restrict Diet(CRD)in Overweight/Obese Patients With Polycystic Ovarian Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai 10th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai 10th People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic ovary syndrome (PCOS) is a common endocrine disorder, with a prevalence of 5% to&#xD;
      15% in premenopausal women. Patients with PCOS presents as abnormal menstruation, ovulation&#xD;
      disorders and/or hyperandrogenemia, and often accompanied by insulin resistance and other&#xD;
      metabolic abnormalities. Visceral fat dysfunction is an important factor in the onset of&#xD;
      PCOS. GLP-1 receptor agonist is a glucagon-like peptide 1 analog, which is related to&#xD;
      improving blood sugar control, weight loss and appetite suppression, and reducing&#xD;
      cardiovascular risk. The purpose of this study was to compare whether the combined treatment&#xD;
      of GLP-1 receptor agonists and calorie restrict diet reduced more visceral fat of&#xD;
      overweight/obese patients with PCOS at the same weight loss (7%) compared with calorie&#xD;
      restrict diet alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the change in visceral adipose tissue</measure>
    <time_frame>until achievement of the weight loss target,an average of 12 weeks</time_frame>
    <description>the change in visceral adipose tissue (pretreatment-post-treatment) after achievement of the weight loss target</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the change in subcutaneous adipose tissue</measure>
    <time_frame>until achievement of the weight loss target,an average of 12 weeks</time_frame>
    <description>the change in subcutaneous adipose tissue (pretreatment-post-treatment) after achievement of the weight loss target</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA IR</measure>
    <time_frame>until achievement of the weight loss target,an average of 12 weeks</time_frame>
    <description>insulin resistance index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometry</measure>
    <time_frame>until achievement of the weight loss target,an average of 12 weeks</time_frame>
    <description>body mass index (kg/m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>menstrual frequency</measure>
    <time_frame>until achievement of the weight loss target,an average of 12 weeks</time_frame>
    <description>number of menstruation in a year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting glucose</measure>
    <time_frame>until achievement of the weight loss target,an average of 12 weeks</time_frame>
    <description>fasting glucose（mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting insulin</measure>
    <time_frame>until achievement of the weight loss target,an average of 12 weeks</time_frame>
    <description>fasting insulin（mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>until achievement of the weight loss target,an average of 12 weeks</time_frame>
    <description>Total cholesterol (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>until achievement of the weight loss target,an average of 12 weeks</time_frame>
    <description>Triglycerides (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-c</measure>
    <time_frame>until achievement of the weight loss target,an average of 12 weeks</time_frame>
    <description>HDL-c (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-c</measure>
    <time_frame>until achievement of the weight loss target,an average of 12 weeks</time_frame>
    <description>LDL-c (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total testosterone</measure>
    <time_frame>until achievement of the weight loss target,an average of 12 weeks</time_frame>
    <description>total testosterone (nmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>free testosterone</measure>
    <time_frame>until achievement of the weight loss target,an average of 12 weeks</time_frame>
    <description>free testosterone (nmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sex hormone binding globulin</measure>
    <time_frame>until achievement of the weight loss target,an average of 12 weeks</time_frame>
    <description>Sex hormone binding globulin(nmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Androstenedione</measure>
    <time_frame>until achievement of the weight loss target,an average of 12 weeks</time_frame>
    <description>Androstenedione(ng/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dehydroepiandrosterone</measure>
    <time_frame>until achievement of the weight loss target,an average of 12 weeks</time_frame>
    <description>Dehydroepiandrosterone (ug/dl)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>GLP-1 RAs and calorie restrict diet group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention with GLP-1 RAs and calorie restrict diet until reaching the target weight loss(7%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>calorie restrict diet group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention with calorie restrict diet until reaching the target weight loss(7%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1 RAs</intervention_name>
    <description>GLP-1 receptor agonist is a glucagon-like peptide 1 analog, which is related to improving blood sugar control, weight loss and appetite suppression, and reducing cardiovascular risk.</description>
    <arm_group_label>GLP-1 RAs and calorie restrict diet group</arm_group_label>
    <other_name>Dulaglutide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>calorie restricted diet</intervention_name>
    <description>Calorie restricted diet can improve insulin sensitivity, liver fat in patients with visceral obesity, and metabolism and hormone levels in obese women with PCOS.</description>
    <arm_group_label>GLP-1 RAs and calorie restrict diet group</arm_group_label>
    <arm_group_label>calorie restrict diet group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female aged 18- 45;&#xD;
&#xD;
          -  Meet Rotterdam criteria;&#xD;
&#xD;
          -  overweight/obesity,BMI≥25kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those who are allergic to the active ingredients of GLP-1 receptor agonists or any&#xD;
             other excipients; patients with a history or family history of medullary thyroid&#xD;
             carcinoma; patients with type 2 multiple endocrine tumor syndrome;&#xD;
&#xD;
          -  Patients with type 1 or type 2 diabetes or diabetic ketoacidosis;&#xD;
&#xD;
          -  Pregnancy, planned pregnancy and breastfeeding women, children;&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic/diastolic blood pressure is 140/90 mmHg);&#xD;
&#xD;
          -  Active heart disease occurred within 3 months;&#xD;
&#xD;
          -  Inflammatory bowel disease, diabetic gastritis or other serious gastrointestinal&#xD;
             diseases;&#xD;
&#xD;
          -  Liver disease, AST or ALT level is twice higher than the upper limit of normal;&#xD;
&#xD;
          -  Kidney disease, creatinine clearance rate is less than 60mL/min;&#xD;
&#xD;
          -  Active or untreated malignant tumors;&#xD;
&#xD;
          -  Acute or chronic pancreatitis;&#xD;
&#xD;
          -  Hemoglobinopathies; hemolytic or chronic anemia;&#xD;
&#xD;
          -  Severe hypoglycemia occurred twice or more within 6 months;&#xD;
&#xD;
          -  Eliminate the use of any drugs that may interfere with the test results (insulin,&#xD;
             α-glucosidase inhibitor, megtinib, DPP-4 inhibitor, GLP-1 receptor agonist or&#xD;
             rosiglitazone)&#xD;
&#xD;
          -  Have received surgical treatment for obesity;&#xD;
&#xD;
          -  Smoking or using any nicotine product; drinking alcohol&#xD;
&#xD;
          -  Expect lifestyle changes (such as diet, exercise, or sleep patterns) during the trial.&#xD;
&#xD;
          -  Currently or recently participating in another clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shen Qu, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Shang hai Tenth People's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Tenth People' Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 10th People's Hospital</investigator_affiliation>
    <investigator_full_name>Zhang Manna</investigator_full_name>
    <investigator_title>Director, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dulaglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

